July/August #146 : Field of Genes

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Torch Song

Service Interruption

AIDS on the Border

Staying Put?

Bad Combos ...and the Women Who Take Them

Move It, Doc!

Stem Cell Surprise

At the Drugstore: Do You Get What You Pay For?

Adherence Tip: It's In the Bag

When to Treat

Tai Chi for T Cells

So Long, Salmonella

Field of Genes

PI Solo Act

Sound Like a Plan?

That's Hot!

Death on the Nile

Operation Iraqi Stigma

Starter Wives

Pos or Not?

Surf's Up!

Postcard From the Edge

HIV Info, Str8 2 UR Fone

Hot Dates-July/August 2008

In or Out?

Mile-High Hopes

Editor's Letter-July/August 2008

Mailbox-July/August 2008

GMHC Treatment Issues-July/August 2008

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

Scroll down to comment on this story.

email print

July / August 2008

Field of Genes

Every day seems to bring a newly discovered link between genes and diabetes, heart disease, cancer or hepatitis. Aside from fueling all those “know your genes” websites, genetic discoveries may someday produce treatments for many diseases. Always on the cutting edge, people with HIV have already been there and have done that. In the past year, two useful advances in HIV medicine have emerged from the science of human genetics.

The player: CCR5, a protein, runs a gateway that HIV uses to enter CD4 cells. Some people inherit two copies of a genetic variation, the CCR5 delta-32 deletion, which makes it difficult to contract HIV. People who inherit just one copy of the variant gene can contract the virus but progress much more slowly toward AIDS.

The game: Discovering this genetic link led to the development of the new class of oral HIV meds, entry inhibitors. Selzentry (maraviroc) was the first of these to get FDA approval; it blocks HIV from attaching to CD4 cells.

The player: The genetic marker HLA-B*5701 is also linked to how fast HIV progresses; people with this variant progress slowly once they have HIV.

The game: Discovering HLA-B*5701 also helped identify people who will develop a hypersensitivity reaction to the HIV drug abacavir (Ziagen, also found in Epzicom and Trizivir). Genetic screening now helps identify such people, so that they can avoid the drug.

Search: genes, diabetes, CD4,

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.